Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.53 |
| ▸ | ACVR2A | P27037 | 4/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21646547 | 0.87 | NLRP3 (0.51) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 | |
| SCHEMBL29691524 | 0.84 | NLRP3 (0.58) | NLRP3ACVR2ATGFBR2PTGDR2 | |
| SCHEMBL22774290 | 0.84 | NLRP3 (0.58) | NLRP3ACVR2ATGFBR2PTGDR2 | |
| SCHEMBL22773925 | 0.83 | NLRP3 (0.57) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 | |
| SCHEMBL23851056 | 0.82 | NLRP3 (0.52) | NLRP3ACVR2ATGFBR2PTGDR2 | |
| SCHEMBL23063393 | 0.82 | NLRP3 (0.46) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 | |
| SCHEMBL22773957 | 0.82 | NLRP3 (0.48) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 | |
| SCHEMBL29467111 | 0.82 | NLRP3 (0.48) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 | |
| SCHEMBL23850999 | 0.81 | NLRP3 (0.51) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 | |
| SCHEMBL22866622 | 0.81 | NLRP3 (0.55) | NLRP3ACVR2ATGFBR2AAK1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 4296/4885TGFBR2 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.